Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
5 c » 25 c (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
5 c » 25 c (Expand Search)
-
11641
-
11642
-
11643
Failure mode of the sample.
Published 2025“…At the same temperature, shear strength increases at a rate of 5.6 MPa/°C with increasing confining pressure; as freezing temperature decreases, the shear strength increases at 0.34 MPa/°C, and cohesion increases at 0.6 MPa/°C. …”
-
11644
Positions of AE probes and strain gauges.
Published 2025“…At the same temperature, shear strength increases at a rate of 5.6 MPa/°C with increasing confining pressure; as freezing temperature decreases, the shear strength increases at 0.34 MPa/°C, and cohesion increases at 0.6 MPa/°C. …”
-
11645
Sampling site.
Published 2025“…At the same temperature, shear strength increases at a rate of 5.6 MPa/°C with increasing confining pressure; as freezing temperature decreases, the shear strength increases at 0.34 MPa/°C, and cohesion increases at 0.6 MPa/°C. …”
-
11646
-
11647
Received AE waves.
Published 2025“…At the same temperature, shear strength increases at a rate of 5.6 MPa/°C with increasing confining pressure; as freezing temperature decreases, the shear strength increases at 0.34 MPa/°C, and cohesion increases at 0.6 MPa/°C. …”
-
11648
Test schemes for soft rocks.
Published 2025“…At the same temperature, shear strength increases at a rate of 5.6 MPa/°C with increasing confining pressure; as freezing temperature decreases, the shear strength increases at 0.34 MPa/°C, and cohesion increases at 0.6 MPa/°C. …”
-
11649
Failure mode of the sample.
Published 2025“…At the same temperature, shear strength increases at a rate of 5.6 MPa/°C with increasing confining pressure; as freezing temperature decreases, the shear strength increases at 0.34 MPa/°C, and cohesion increases at 0.6 MPa/°C. …”
-
11650
S1 Table -
Published 2025“…At the same temperature, shear strength increases at a rate of 5.6 MPa/°C with increasing confining pressure; as freezing temperature decreases, the shear strength increases at 0.34 MPa/°C, and cohesion increases at 0.6 MPa/°C. …”
-
11651
AE monitoring system.
Published 2025“…At the same temperature, shear strength increases at a rate of 5.6 MPa/°C with increasing confining pressure; as freezing temperature decreases, the shear strength increases at 0.34 MPa/°C, and cohesion increases at 0.6 MPa/°C. …”
-
11652
MTS-370.25 fatigue resting system.
Published 2025“…At the same temperature, shear strength increases at a rate of 5.6 MPa/°C with increasing confining pressure; as freezing temperature decreases, the shear strength increases at 0.34 MPa/°C, and cohesion increases at 0.6 MPa/°C. …”
-
11653
Schematic diagram of the AE testing system.
Published 2025“…At the same temperature, shear strength increases at a rate of 5.6 MPa/°C with increasing confining pressure; as freezing temperature decreases, the shear strength increases at 0.34 MPa/°C, and cohesion increases at 0.6 MPa/°C. …”
-
11654
Strain at different positions of the sample.
Published 2025“…At the same temperature, shear strength increases at a rate of 5.6 MPa/°C with increasing confining pressure; as freezing temperature decreases, the shear strength increases at 0.34 MPa/°C, and cohesion increases at 0.6 MPa/°C. …”
-
11655
Proposal for a diagnostic and therapeutic algorithm to manage rheumatic and musculoskeletal disorders persisting after acute chikungunya (CHIK) infection, with the following abbrev...
Published 2015“…<sup>5</sup>Immune-modulating biologic agents = rheumatologist prescription among anti-TNF (etanercept 25mg twice a week, infliximab 3–5 mg/kg/ 6–8 weeks, adalimumab 40 mg/ 2 weeks, golimumab 50mg/month), abatacept (inhibition of T-lymphocyte activation, 500–1000 mg/ 4 weeks), rituximab (depletion of B-lymphocytes, 1000 mg repeated at 2 weeks) and tocilizumab (inhibition of interleukin-6 receptor, 8 mg/ kg/ 2 weeks). …”
-
11656
-
11657
-
11658
-
11659
-
11660